Cerebrovascular reactivity after cessation of menopausal hormone treatment

J. N. Barnes, R. E. Harvey, N. A. Eisenmann, K. B. Miller, M. C. Johnson, S. M. Kruse, B. D. Lahr, Michael Joseph Joyner, Virginia M Miller

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective: Women who are currently using menopausal hormone therapy (MHT) have higher cerebrovascular reactivity when compared with postmenopausal women who are not taking MHT; however, the effect of cessation of MHT on cerebrovascular reactivity is not known. Given that MHT can have structural and activational effects on vascular function, this study was performed to characterize cerebrovascular reactivity following cessation of MHT in women at low risk for cerebrovascular disease. Methods: Cerebrovascular reactivity was measured in a subset of women from the Kronos Early Estrogen Prevention Study (KEEPS) 3 years after cessation of the study drug (oral conjugated equine estrogen, transdermal 17β-estradiol, or placebo [PLA]). Results: Age, body mass index, and blood pressure were comparable among groups. At rest, the middle cerebral artery velocity (MCAv), cerebrovascular conductance index, mean arterial pressure, and cerebral pulsatility index did not differ among groups. Slope-based summary measures of cerebrovascular reactivity did not differ significantly among groups. However, utilizing repeated-measures modeling, there was a significant upward shift in MCAv responses (p = 0.029) in the combined MHT group compared with the PLA group. Conclusion: MHT has a marginal sustained effect on cerebrovascular reactivity when measured 3 years after cessation of hormone treatment.

Original languageEnglish (US)
JournalClimacteric
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Hormones
Middle Cerebral Artery
Therapeutics
Placebos
Conjugated (USP) Estrogens
Cerebrovascular Disorders
Withholding Treatment
Group Psychotherapy
Blood Vessels
Estradiol
Arterial Pressure
Estrogens
Body Mass Index
Blood Pressure
Pharmaceutical Preparations

Keywords

  • blood pressure
  • Cerebral hemodynamics
  • estrogen
  • menopause
  • sex hormones

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Barnes, J. N., Harvey, R. E., Eisenmann, N. A., Miller, K. B., Johnson, M. C., Kruse, S. M., ... Miller, V. M. (Accepted/In press). Cerebrovascular reactivity after cessation of menopausal hormone treatment. Climacteric. https://doi.org/10.1080/13697137.2018.1538340

Cerebrovascular reactivity after cessation of menopausal hormone treatment. / Barnes, J. N.; Harvey, R. E.; Eisenmann, N. A.; Miller, K. B.; Johnson, M. C.; Kruse, S. M.; Lahr, B. D.; Joyner, Michael Joseph; Miller, Virginia M.

In: Climacteric, 01.01.2018.

Research output: Contribution to journalArticle

Barnes JN, Harvey RE, Eisenmann NA, Miller KB, Johnson MC, Kruse SM et al. Cerebrovascular reactivity after cessation of menopausal hormone treatment. Climacteric. 2018 Jan 1. https://doi.org/10.1080/13697137.2018.1538340
Barnes, J. N. ; Harvey, R. E. ; Eisenmann, N. A. ; Miller, K. B. ; Johnson, M. C. ; Kruse, S. M. ; Lahr, B. D. ; Joyner, Michael Joseph ; Miller, Virginia M. / Cerebrovascular reactivity after cessation of menopausal hormone treatment. In: Climacteric. 2018.
@article{832da76d04e749f5a0b039d07cf71e36,
title = "Cerebrovascular reactivity after cessation of menopausal hormone treatment",
abstract = "Objective: Women who are currently using menopausal hormone therapy (MHT) have higher cerebrovascular reactivity when compared with postmenopausal women who are not taking MHT; however, the effect of cessation of MHT on cerebrovascular reactivity is not known. Given that MHT can have structural and activational effects on vascular function, this study was performed to characterize cerebrovascular reactivity following cessation of MHT in women at low risk for cerebrovascular disease. Methods: Cerebrovascular reactivity was measured in a subset of women from the Kronos Early Estrogen Prevention Study (KEEPS) 3 years after cessation of the study drug (oral conjugated equine estrogen, transdermal 17β-estradiol, or placebo [PLA]). Results: Age, body mass index, and blood pressure were comparable among groups. At rest, the middle cerebral artery velocity (MCAv), cerebrovascular conductance index, mean arterial pressure, and cerebral pulsatility index did not differ among groups. Slope-based summary measures of cerebrovascular reactivity did not differ significantly among groups. However, utilizing repeated-measures modeling, there was a significant upward shift in MCAv responses (p = 0.029) in the combined MHT group compared with the PLA group. Conclusion: MHT has a marginal sustained effect on cerebrovascular reactivity when measured 3 years after cessation of hormone treatment.",
keywords = "blood pressure, Cerebral hemodynamics, estrogen, menopause, sex hormones",
author = "Barnes, {J. N.} and Harvey, {R. E.} and Eisenmann, {N. A.} and Miller, {K. B.} and Johnson, {M. C.} and Kruse, {S. M.} and Lahr, {B. D.} and Joyner, {Michael Joseph} and Miller, {Virginia M}",
year = "2018",
month = "1",
day = "1",
doi = "10.1080/13697137.2018.1538340",
language = "English (US)",
journal = "Climacteric",
issn = "1369-7137",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Cerebrovascular reactivity after cessation of menopausal hormone treatment

AU - Barnes, J. N.

AU - Harvey, R. E.

AU - Eisenmann, N. A.

AU - Miller, K. B.

AU - Johnson, M. C.

AU - Kruse, S. M.

AU - Lahr, B. D.

AU - Joyner, Michael Joseph

AU - Miller, Virginia M

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Objective: Women who are currently using menopausal hormone therapy (MHT) have higher cerebrovascular reactivity when compared with postmenopausal women who are not taking MHT; however, the effect of cessation of MHT on cerebrovascular reactivity is not known. Given that MHT can have structural and activational effects on vascular function, this study was performed to characterize cerebrovascular reactivity following cessation of MHT in women at low risk for cerebrovascular disease. Methods: Cerebrovascular reactivity was measured in a subset of women from the Kronos Early Estrogen Prevention Study (KEEPS) 3 years after cessation of the study drug (oral conjugated equine estrogen, transdermal 17β-estradiol, or placebo [PLA]). Results: Age, body mass index, and blood pressure were comparable among groups. At rest, the middle cerebral artery velocity (MCAv), cerebrovascular conductance index, mean arterial pressure, and cerebral pulsatility index did not differ among groups. Slope-based summary measures of cerebrovascular reactivity did not differ significantly among groups. However, utilizing repeated-measures modeling, there was a significant upward shift in MCAv responses (p = 0.029) in the combined MHT group compared with the PLA group. Conclusion: MHT has a marginal sustained effect on cerebrovascular reactivity when measured 3 years after cessation of hormone treatment.

AB - Objective: Women who are currently using menopausal hormone therapy (MHT) have higher cerebrovascular reactivity when compared with postmenopausal women who are not taking MHT; however, the effect of cessation of MHT on cerebrovascular reactivity is not known. Given that MHT can have structural and activational effects on vascular function, this study was performed to characterize cerebrovascular reactivity following cessation of MHT in women at low risk for cerebrovascular disease. Methods: Cerebrovascular reactivity was measured in a subset of women from the Kronos Early Estrogen Prevention Study (KEEPS) 3 years after cessation of the study drug (oral conjugated equine estrogen, transdermal 17β-estradiol, or placebo [PLA]). Results: Age, body mass index, and blood pressure were comparable among groups. At rest, the middle cerebral artery velocity (MCAv), cerebrovascular conductance index, mean arterial pressure, and cerebral pulsatility index did not differ among groups. Slope-based summary measures of cerebrovascular reactivity did not differ significantly among groups. However, utilizing repeated-measures modeling, there was a significant upward shift in MCAv responses (p = 0.029) in the combined MHT group compared with the PLA group. Conclusion: MHT has a marginal sustained effect on cerebrovascular reactivity when measured 3 years after cessation of hormone treatment.

KW - blood pressure

KW - Cerebral hemodynamics

KW - estrogen

KW - menopause

KW - sex hormones

UR - http://www.scopus.com/inward/record.url?scp=85060474412&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060474412&partnerID=8YFLogxK

U2 - 10.1080/13697137.2018.1538340

DO - 10.1080/13697137.2018.1538340

M3 - Article

C2 - 30661405

AN - SCOPUS:85060474412

JO - Climacteric

JF - Climacteric

SN - 1369-7137

ER -